Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription Articles published in J Clin Psychopharmacol Retrieve available abstracts of 52 articles: HTML format

Single Articles

May 2025
1. JOGI L, Praveen P, Shibu A, Narasimhappa K, et al
   The Impact of Therapeutic Drug Monitoring on Clozapine Dosing and Clinical Outcome in a Tertiary Care Center in India: A Retrospective Study.
   J Clin Psychopharmacol. 2025;45:251-257.
   PubMed     Abstract available
   
   
   April 2025
2. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
   Plasma Clozapine in Treatment Refractory Schizophrenia: What Is the Target Range?
   J Clin Psychopharmacol. 2025 Apr 9. doi: 10.1097/JCP.0000000000002007.
   PubMed     Abstract available
   
   
   
3. COLIJN MA
   Clozapine Use Among Individuals With Schizophrenia Occurring on the Background of Intellectual Disability and Rare Genetic Variation: A Retrospective Chart Review.
   J Clin Psychopharmacol. 2025 Apr 7. doi: 10.1097/JCP.0000000000002000.
   PubMed     Abstract available
   
   
   
4. KIKUCHI Y, Sakata M, Ikawa K, Kume D, et al
   Weekly Changes in the Clozapine Concentration-to-Dose Ratio During Clozapine Titration in Japanese Patients With Schizophrenia.
   J Clin Psychopharmacol. 2025 Apr 7. doi: 10.1097/JCP.0000000000002003.
   PubMed     Abstract available
   
   
   March 2025
5. PACILIO RM, Geller JA
   Persistent Psychosis Associated With Intravenous Ketamine in a Patient Using Cannabis: A Case Report and Literature Review.
   J Clin Psychopharmacol. 2025 Mar 27. doi: 10.1097/JCP.0000000000001995.
   PubMed    
   
   
   
6. YE CW, Lin CH, Wang SJ
   Olanzapine-Associated Hyperbilirubinemia in an Adolescent With Autistic Spectrum Disorder Comorbid With Schizophrenia: A Case Report.
   J Clin Psychopharmacol. 2025 Mar 26. doi: 10.1097/JCP.0000000000001974.
   PubMed    
   
   
   February 2025
7. DODDI SR, Pham F, Wineke J, Marano C, et al
   Protracted Psychiatric Complications Including Psychosis in a Middle-Aged Man After COVID-19 Vaccination: A Case Report.
   J Clin Psychopharmacol. 2025 Feb 10. doi: 10.1097/JCP.0000000000001969.
   PubMed    
   
   
   
8. ELOMA-ATA A, Wafy F, Parikh A, Tusher A, et al
   A Case of Hypothermia Associated With the Use of Multiple Antipsychotics in a Patient With Late-Onset Schizophrenia.
   J Clin Psychopharmacol. 2025 Feb 7. doi: 10.1097/JCP.0000000000001961.
   PubMed    
   
   
   
9. GOFF DC
   At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy).
   J Clin Psychopharmacol. 2025 Feb 6. doi: 10.1097/JCP.0000000000001959.
   PubMed    
   
   
   January 2025
10. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Clozapine Dosage in Treatment-Refractory Schizophrenia: A Reply to Dr Grover and Colleagues.
    J Clin Psychopharmacol. 2025 Jan 14. doi: 10.1097/JCP.0000000000001955.
    PubMed    
    
    
    
11. OLMOS I, Ricciardi C, Mato M, Guevara N, et al
    Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia.
    J Clin Psychopharmacol. 2025;45:20-27.
    PubMed     Abstract available
    
    
    December 2024
12. EL JABIRY SE, Benkarroum F, Barrimi M, Elghazouani F, et al
    Risperidone-Associated Stuttering in Patient With Schizophrenia: A Case Report.
    J Clin Psychopharmacol. 2024 Dec 31. doi: 10.1097/JCP.0000000000001950.
    PubMed    
    
    
    
13. HOOBERMAN AJ, Martinez NJ, Stojcevski M, Wechsler B, et al
    A Case of Tacrolimus-Associated Psychosis.
    J Clin Psychopharmacol. 2024 Dec 31. doi: 10.1097/JCP.0000000000001956.
    PubMed    
    
    
    
14. BUESKING SC, Kriz CR, Jarvis SP, Nelson LA, et al
    Recognition of Clozapine-Associated Eosinopenia in Patients With Treatment-Resistant Schizophrenia: A Report of 3 Cases and Literature Review.
    J Clin Psychopharmacol. 2024 Dec 17. doi: 10.1097/JCP.0000000000001947.
    PubMed    
    
    
    
15. TAKEUCHI H, Uchida H
    Efficacy and Safety of Dose Increase From 40 mg/d to 80 mg/d of Lurasidone in Patients With Schizophrenia: A Post Hoc Analysis of Extension Trial.
    J Clin Psychopharmacol. 2024 Dec 2. doi: 10.1097/JCP.0000000000001943.
    PubMed     Abstract available
    
    
    November 2024
16. O'CONNELL P, Alsaffar M
    The Treatment of Iatrogenic Anorgasmia in a Male Patient on Clozapine for Treatment-Resistant Schizophrenia: The Role of Pseudoephedrine.
    J Clin Psychopharmacol. 2024 Nov 12. doi: 10.1097/JCP.0000000000001930.
    PubMed    
    
    
    
17. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Effect of Valproate Coprescription on Clozapine Pharmacokinetics in Clinical Practice.
    J Clin Psychopharmacol. 2024;44:561-569.
    PubMed     Abstract available
    
    
    
18. GURCAN G, Atalay B, Deveci E
    Clozapine-Associated Sialorrhea: A Literature Review.
    J Clin Psychopharmacol. 2024;44:570-575.
    PubMed     Abstract available
    
    
    
19. LOCHMANN VAN BENNEKOM MWH, Gijsman HJ, IntHout J, Verkes RJ, et al
    Antipsychotic Polypharmacy in Time Course: Evidence for a Cross-titration Trap.
    J Clin Psychopharmacol. 2024;44:545-550.
    PubMed     Abstract available
    
    
    October 2024
20. PEREZ-SAGASETA DE ILURDOZ I, Aparicio-Dominguez A, Yelmo-Cruz S, Cardenes-Moreno C, et al
    alpha-PVP Associated Psychosis: A Case Report.
    J Clin Psychopharmacol. 2024 Oct 11. doi: 10.1097/JCP.0000000000001918.
    PubMed    
    
    
    September 2024
21. MITOMA R, Hirano S, Nakao T
    Successful Management of ECT-Resistant Interictal Psychosis With Clozapine: A Case Report.
    J Clin Psychopharmacol. 2024;44:527-528.
    PubMed    
    
    
    
22. DI LISI A, Pupo S, Menchetti M, Pelizza L, et al
    Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice.
    J Clin Psychopharmacol. 2024;44:502-508.
    PubMed     Abstract available
    
    
    
23. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations and the Clozapine/Norclozapine Ratio : Effect of Dose, Sex, and Cigarette Smoking.
    J Clin Psychopharmacol. 2024;44:492-501.
    PubMed     Abstract available
    
    
    August 2024
24. BUCHANAN RW, Werkheiser AE, Michel H, Zaranski J, et al
    Prebiotic Treatment in People With Schizophrenia.
    J Clin Psychopharmacol. 2024 Aug 16. doi: 10.1097/JCP.0000000000001899.
    PubMed     Abstract available
    
    
    July 2024
25. HAUSER RA, Barkay H, Fernandez HH, Jimenez-Shahed J, et al
    Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    J Clin Psychopharmacol. 2024;44:386-396.
    PubMed     Abstract available
    
    
    
26. GOUDA M, Abe M, Watanabe Y, Kato TA, et al
    Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association.
    J Clin Psychopharmacol. 2024;44:378-385.
    PubMed     Abstract available
    
    
    
27. PACILIO RM, Dalack GW
    Asthma and Atypical Antipsychotics: A Systematic Literature Review and Case Report of Respiratory Side Effects With Lurasidone, Cariprazine, and Lumateperone.
    J Clin Psychopharmacol. 2024;44:436-437.
    PubMed    
    
    
    May 2024
28. KARAL BN, Ozdemir YE, Karayagmurlu A
    The Management of Very Early-Onset Schizophrenia With an Olanzapine and Amisulpride Combination.
    J Clin Psychopharmacol. 2024 May 2. doi: 10.1097/JCP.0000000000001853.
    PubMed    
    
    
    
29. OKADA Y, Inada K, Akazawa M
    Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.
    J Clin Psychopharmacol. 2024;44:263-271.
    PubMed     Abstract available
    
    
    
30. DE LEON J
    Can Slow Personalized Titration Using C-Reactive Protein Monitoring Decrease the High Rates and Mortality of Clozapine-Associated Myocarditis Seen in Some Countries? A Call for Research.
    J Clin Psychopharmacol. 2024;44:212-219.
    PubMed     Abstract available
    
    
    April 2024
31. SCALA M, Martinez Trapote P, Rodriguez-Jimenez R, Pecorino B, et al
    Managing a Treatment-Resistant Schizophrenia Spectrum Disorder With a Hormonal Twist in a Female Patient: A Case Report of a Progestin-Only Pill.
    J Clin Psychopharmacol. 2024 Apr 9. doi: 10.1097/JCP.0000000000001836.
    PubMed    
    
    
    March 2024
32. KORKMAZ SA, Koca E, Yilmaz O, Ozbek T, et al
    Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
    J Clin Psychopharmacol. 2024 Mar 5. doi: 10.1097/JCP.0000000000001837.
    PubMed     Abstract available
    
    
    
33. NAGANO M, Susuta Y, Masui H, Watanabe Y, et al
    Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    J Clin Psychopharmacol. 2024;44:107-116.
    PubMed     Abstract available
    
    
    February 2024
34. MORI Y, Watanabe K, Suzuki Y, Ono H, et al
    Clozapine-Associated Myocarditis in a Patient With Schizophrenia Taking Lemborexant: A Case Report.
    J Clin Psychopharmacol. 2024 Feb 8. doi: 10.1097/JCP.0000000000001817.
    PubMed    
    
    
    
35. DIMA A, Abdelsamie A, Clark-Castillo R, Webb-Wilson H, et al
    Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features.
    J Clin Psychopharmacol. 2024 Feb 5. doi: 10.1097/JCP.0000000000001819.
    PubMed    
    
    
    January 2024
36. WATANABE M, Misawa F, Takeuchi H
    Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study.
    J Clin Psychopharmacol. 2024 Jan 26. doi: 10.1097/JCP.0000000000001804.
    PubMed     Abstract available
    
    
    
37. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Reply to a Letter to the Editors From Dr de Souza and colleagues: "Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity".
    J Clin Psychopharmacol. 2024;44:76-78.
    PubMed    
    
    
    
38. DE SOUZA JUNIOR SA, Cavalcante da Rocha ME, Marques Andrade AG, Fernandes de Moraes CL, et al
    Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity.
    J Clin Psychopharmacol. 2024;44:74-76.
    PubMed    
    
    
    
39. MOHAMMAD-GHOLIZAD F, Karimzadeh I, Moghimi-Sarani E, Arshadi M, et al
    Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial
    J Clin Psychopharmacol. 2024;44:9-15.
    PubMed     Abstract available
    
    
    
40. KARACAM DOGAN M, Yildiz FG, Temucin CM, Ertugrul A, et al
    Effects of Clozapine on Cortical Inhibition: A Transcranial Magnetic Stimulation Follow-up Study.
    J Clin Psychopharmacol. 2024;44:16-24.
    PubMed     Abstract available
    
    
    November 2023
41. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Reply to Dr Yucel's Comments on the Article "Long-term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555-556.
    PubMed    
    
    
    
42. YUCEL A
    Critical Feedback on Article by Lee and Colleagues: "Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555.
    PubMed    
    
    
    
43. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis?: A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023;43:551-553.
    PubMed    
    
    
    
44. MAGISTRI C, Mellini C
    Clozapine-Associated Agranulocytosis: A Systematic Review. Is It Really So Frighteningly Common?
    J Clin Psychopharmacol. 2023;43:527-533.
    PubMed     Abstract available
    
    
    
45. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis: A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023;43:511-513.
    PubMed     Abstract available
    
    
    September 2023
46. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis? A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023 Sep 29. doi: 10.1097/JCP.0000000000001766.
    PubMed    
    
    
    
47. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis. A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023 Sep 7. doi: 10.1097/JCP.0000000000001758.
    PubMed     Abstract available
    
    
    
48. TKACH N, Opler DJ
    A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023;43:481-482.
    PubMed    
    
    
    
49. DE LIMA DN JR, Frota IJ, Macedo DS, Sanders LLO, et al
    Alpha Lipoic Acid for Schizophrenia: Future Investigations With Low Doses and Treatment-Resistant Patients-Reply to Letter by Kishi and Colleagues.
    J Clin Psychopharmacol. 2023;43:478-479.
    PubMed    
    
    
    
50. KISHI T, Sakuma K, Miura G, Ito Y, et al
    Alpha Lipoic Acid for Schizophrenia: A Systematic Review and Meta-analysis.
    J Clin Psychopharmacol. 2023;43:477-478.
    PubMed    
    
    
    
51. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023;43:472-474.
    PubMed    
    
    
    
52. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023;43:468-469.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.